FOSUN PHARMA
复星医药

2022

1

2

3

4

5

6

ԿԱՐԾ

1/3

ġ

439.52

+12.66% YoY

ڤ

ġ

139.38

+2.49% YoY

31.7%

”Ḥ 8 ”Ḥ ġ

ت

30%

Ī ₦ت25%

ˇ ʌ

ک Ỳ ₣

38.73

+18.17% YoY

ʌ4 ∟ ♪ گّ ʃ

42.18

+7.10% YoY

MSCI-ESG ₰ ˎ

A

BBB A

2/3

PD-1
MSI-H sqNSCLC ES-SCLC SCLC
FDA EC
MAA EMA *
2022
CAR-T
10
13
III
mRNA
*
RT002 **Tenapanor** **NHE3**
III

Parsabiv ®
Organon Eurofarma
Abbott

Syneos Health
PD-1
Gland
Pharma
Cenexi
CDMO
Sisram
66%

SCLC

3/3

٧ ٦

¨Ḥ

▫ ڈ

Ỉ ٨ ▌

ف ٦ ٧ Ᵽ

ڒ ٧ ū

GT1-GT6

Ỉ ڻ

ˆ ¨O ® ٹ ○

5 ǐ

ي ṭ ٨

˝...┼˜ ˚

٨ ٧ Ỉ

CMC

˜ ڳ ڀ **SAB**

Scientific Advisor Board

2022 674

ᑕ ᒐ ᕐᑭ ᐅ	2021	2022	YoY
4 ᑫ	390.11	439.52	*12.7%*
ᐱ ᒻ ᑦ	47.29	37.31	*-21.1%*
Ỳ ᓂ	32.77	38.73	*18.2%*
ᐊ4 ᒪ ᓱ ᕐᓂ ᑐ	39.38	42.18	*7.1%*
ᑐ ᐅ	49.78	58.85	*18.2%*
ᑐ - ᐊ	38.37	43.02	*12.1%*
ᐅ £ ᐱ ᑫ ᑐ	1.85	1.43	*-22.7%*
ᐊ ₦ ( )	30%	30%	-

- ᐊ ᐊ ᕕ	2021	2022
Rs ᕿ	48.1%	47.3%
ᓄ - ᐊ ᕿ	23.3%	20.9%
ᐊ ₱ - ᐊ ᕿ	8.3%	8.7%
ᑐ - ᐊ ᕿ	9.8%	9.8%
ᒐ - ᐊ ᕿ	1.2%	1.5%
Rs ᕿ ᓄ - ᐊ ᕿ	24.8%	26.4%

ᑕ ᒥ	2021	2022
ᒪ ᐅ...ᕐᓂ	103.17	162.41
ᒻ ᐅ... ᐱ	391.96	445.82
ᑐ ₦ ᕿ	1.04	1.06
ᓛ ₦ ᕿ	0.85	0.85
ᐅ... u ᕿ	48.2%	49.5%

-1.42 15.93 , BNTX BNTX -10 37.31 21.10%

1 2) 3 2.96 1 2 3

2022 7 44.8 A A 1 2 3

1
2
3
4

BNTX

2021

2022


DRG/DIP


02
01
03
CNS
50%
FIC+BIC

	كٖ	كٖ ذَ
ٖH	® PD-1 *MSI-H*	® CAR-T
	® CD20	® HER2
	®	®
		®


1994
2002-2004
2008-2010
2013
2015
2017
2018-2019
2020
2021
2022
Alma
Gland Pharma
Tridem Pharma
Intuitive Surgical
Kite Pharma
FOSUNKite
BIONTECH
mRNA
HELSINN
Akynzeo
Aloxi
Anamorelin
sobi
RT002
cenexi
Gland Pharma
CDMO
Cenexi
AMGEN 安进
Parsabiv®
真实生物
Insilico Medicine
AI

FES Fosun Ecosystem/Entrepreneurship System

SRM

INNOX

2022 FES

6,000

OBM OTC

2022 20.87% 2.46

1/2

Gland Pharma 2.1 **Cenexi**

CDMO

5

2022

ICRC

Gland Pharma

2023 2

Gland Pharma

CDMO

5

16 GPO

PD-1 11

ES-SCLC

Syneos Health PD-1

Sisram **1.4**

28.2% Sisram **40.5%**

2/2



MSCI-ESG

A

2022

BBB

2021

BB

2020

E nvironment

EHS

EHS

2021-2026 EHS

2022 115.36

337,806 3.2%

S ocial

337,806



/ADC

RNA

1

2

BNTX

˝A	h ǐ
55.22	26%[1]

+39.44% YoY

® HER2 ®

®

TNF- ®

PD-1 ®

ɔ̄ ̈A ˏ ´I ´Y ˥ ɷ ̈I ˧˩

ɔ̄ ̈A **50.97** +13.62%

YoY 85%

16.54% 35.52

11.53%

30%

260 2022

249

16 PCT 17

48



-

®

Ł ي ⅛ ˆ SCLC ˈˈ ˇA PD-1 ˇA

3.4

2022 ᾴ **9** ĭ

PD-1

Ŋ ἂ ځ '

MSI-H

_ ,

SCLC FDA EC

ɔ̄ ˜ ̀Ω ɔ

ES-SCLC III

(OS)

OS 15.4

10.9 24 43.1% 7.9%

JAMA Nature Medicine

British Journal of Cancer

nature medicine JAMA The Journal of the American Medical Association BJC Journal of Cancer British

ɛ ɛ ɛ

27 110 30%

400

DTP



2022 ه ۲

ه	L 4	گ Ạ	ۆ ۱
	10	5	mRNA ® HER2 ® CD20 ®
5	10	3	® ®
3	5	8	® PD-1 ® VERO ® ® 8
1	3	31	® TNF- ® ® ® 31

2022 ᑕ ʼ

2 ̈Ḥ 1 Alma Ted 2
CBD+Professional Skincare Solution
CBD
3 LMNT one

62% **66%**

O ♪



2022 ̈Ḥ

Alma Ted

LMNT one

CBD+Professional Skincare Solution



2017		2016	Intuitive Surgical
		2017	ー 7 . ב ト ̃Ω̣
2019		Xi	
2020			“ ”
	200	800	
2021	ו ו̈	̈Ḥ	1,700
			4,000
2022		ژ ̄ כ	
		31.2	
ו ́Y			

ژ ̄ כ Ł ه

ב

ו ו̈ ừ ŭ ū

2022 55

ت**300**

10

2000 FDA 2022 12 31

7,544 55,000

1,000

Ion ̓Ω̣ ו ́ ̓Ḥ ū

2019 Ion

FDA

2021 10 Ion

Ion

2022 ´ Ḥ ⊏ ʼ

& >15%

2022 6 F-C800p 2021 F-i3000

FCi

2022 4 2019-nCoV

CE BfArM

2022 5 PCR CE





´ Ḥ

ǫ̌

ɔ̀ w / ɔ̀ ʌ

ǔ ṇ

ɟ̈ ɯ

ť

^

ڢ ڢ



ڢ 1



ڢ



2011-2017

2018-2020

2021

1
2
3

33.56%

ـ

ـ

ﻻ

ﺃ ﺣ ﺇ

6,333 *

ﺟ ﺍ

JCI∩O ﻭ ﻻ

“ ”

JVF ● ▓

ﻗ ﺍ

ﺃ ﺣ ﺇ

ﻭ ﻗ ﺃ ﻳ

佛山禅醫 Foshan Fosun Chancheng Hospital 佛山复星禅诚医院

JCI国际认证医院 Organization Accredited by Joint Commission International

1,750

2022 21.45 1.11

86.47%

深圳恒生医院 SHENZHEN HENGSHENG HOSPITAL

600

2017 11 9.09

60%

广州市第一人民医院

800

900

2022 1 70%

ﻳ ﻗ ﺍ

宿迁市钟吾医院 SUQIAN SHOUNAN HOSPITAL 宿迁市肿瘤医院 SUQIAN CANCER HOSPITAL

卓尔荟 JOYFUL WAY

安徽济民肿瘤医院 ANHUI JIMIN CANCER HOSPITAL

温州老年病醫院 WENZHOU GERIATRIC HOSPITAL

星家整形外科医院 SHANGHAI STAR SURGERY HOSPITAL

湖北省人民医院 医联体 武汉济和医院 HUBEI GENERAL HOSPITAL MEDICAL CONSORTIUM WUHAN JIHE HOSPITAL

STAR HOSPITAL 星晨妇儿 上海复星医疗旗下高品质医院 医保定点医院

2022 12 *

FOSUN HEALTH
复星健康
HIS







ἔ ἶ ο ῳ ᾿ ᾴ ι € **4,066** ₦ ᾿ **4.27%**

“ ” ἔ ἶ

ˆ ᾿ ῳ ᾿ ᾴ € **1,209** ₦ ᾿ **11.77%**

ἔ ἶ

ᾶ ♪ ᾴ € **330** ₦ ᾿ **13.49%**

ط

1/2

2/2

		/ ū	ĉ '		IND	1 ī	2 ī	3 ī	NDA
	FS-1502	HER2	HER2						
			HER2						
	FS-1502+	HER2+PD-1	HER2						
	HLX14 [1] ORGANON	RANKL							
	HLX26	LAG-3							
	HLX35[2] BINACEA	EGFR×4-1BB		2022 1 NMPA		2022 6		I	
	HLX301	PD-L1×TIGIT		2022 2		2022 3 NMPA		7	
	HLX15	CD38							
	HLX13	CTLA-4							
		EPO							
		INSR							
	50R	INSR							
		GLP-1							
	RT002		GL						
			CD	2022 1 ż					

1 Organon
2 Binacea

3 2023 2 28

1/2

⅛ ۸ ڻ	´ ﮬ ﮭ	/ ū	' ځ		IND	1 Ī	2 Ī	3 Ī	NDA
	FCN-437c	CDK4/6	(1L)	2022 1 NMPA III I					
			(2L)	2022 1 III					
	SAF-189	ALK		2022 1 NMPA III I					
		ROS1							
	HLX-208	BRAF V600E	LCH ECD	2022 1 NMPA Ib/II					
	FCN-159	MEK	I						
				2022 5 NMPA					
				2022 5 NMPA					
	YP01001	VEGFR							
	FCN-338	BCL-2	B	I					
	FH-2001	FGFR/PD-L1							

2023 2 28

2/2

⅛ ۂ ڻ	´ אֶگ	/ ū	' ځ	IND	1 ī	2 ī	3 ī	NDA
		TPO-R	ITP	2022 12 NDA NMPA				
	Tenapanor	NHE 3	(ESRD-HD)					
		-						
	Tenapanor	NHE 3	(IBS-C)	I				
	FCN-342	URAT1						
	Molnupiravir	RNA						
	Paxlovid	3CL						
	BNT162b2	-					EUA	
	PA-824	-	/ XDR-TB MDR-TB	Pretomanid*				
	Opicapone	COMT		Ongentys*				
	Fortacin	-		*				
	ET-26	-		2022 7	II			

2023 2 28

“ “ ” LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun ” , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

www.fosunpharma.com